Welcome to AVaTAR MedTech, where innovation meets compassion. Our inaugural product, AVaTAR (Aortic Valve Trileaflet Autologous Reconstruction), stands as a groundbreaking surgical method and set of medical devices designed to reconstruct the aortic or the pulmonary valve in children and adults with autologous tissue.
Valvular heart diseases, a subset of heart conditions, frequently involve the aortic or the pulmonary valve, which can either not open properly (stenosis), not close correctly (regurgitation/insufficiency) or suffer from the two problems.
It affects more than 9.4 million people worldwide, especially in developed countries.
It is the most common cause of heart valve disease and affects more than 40.5 million people worldwide, of which 2.7 million are children.
Bicuspid aortic valve is the most common form of congenital heart disease, occurring in 0.71% of the general population.
Moderate or more severe aortic regurgitation was estimated to be prevalent in approximately 0.5% of the total US population.
It is one of the deadliest valvular pathologies, with 1.1 million cases globally and causing 66,000 deaths annually.
Representing 12 per 1,000 newborns.
50% of children born with heart defects require surgery in their first year of life.
Children and adolescents under 18 years old suffer from congenital aortic stenosis worldwide, which comprises 4% of congenital heart defects and ranks among the top 8 most common.
Crafted with precision, our medical solutions are designed to cater to the unique needs of pediatric patients, ensuring optimal functionality and safety.
Discover a revolutionary method that not only reconstructs valves perfectly and rapidly but also ensures that no part of the device remains in the patient's body, prioritizing safety and long-term well-being.
Experience the efficiency of our technology with rapid deployment, offering a swift and reliable solution for reconstructing aortic or pulmonary valves in both children and adults.
Our innovative approach allows our devices to adapt seamlessly to the natural growth of pediatric patients, providing a sustainable and effective solution over time.
Say goodbye to the complications of anticoagulation. Our method ensures a safe and effective valve reconstruction without the need for ongoing anticoagulant treatments.
In children, treatment is complicated by the lack of suitably sized valves and rapid growth, often leading to early mortality and limited use of prosthetic valves.
Adult treatments include valve repair/replacement and complex surgeries, but face challenges like the need for lifelong anticoagulation with mechanical valves, lower durability of biological valves, and complications in complex procedures.
